

What is Evusheld?

Your physician /provider may have recommended that you receive Evusheld. What is Evusheld? Who is the target population for this medicine?

Evusheld is composed of two recombinant human monoclonal antibodies, tixagevimab co-packaged with cilgavimab, which is authorized for use under an EUA (emergency use authorization) for the pre-exposure prophylaxis/prevention of COVID-19 in adults and pediatric individuals who are 12 years of age and older weighing at least 40 kg.

Evusheld is for patients:

- who are not currently infected with SARS-CoV-2 **and**
- who have not had a known recent exposure to an individual infected with SARS-CoV-2 **and**
- who have moderate to severe immune compromise due to a medical condition

OR

- on immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination (active treatment for cancer, has had organ transplant and is on immunosuppressive medications, has primary deficiency, has advanced or untreated HIV, active treatment with high-dose corticosteroids, which is at least 20mg prednisone or equivalent per day when administered for more than 2 weeks, on alkylating agents, biologic agents, such as B-cell depleting agents like Rituximab)

OR

-for whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (for instance, severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

How is Evusheld given?

Evusheld is prepared and administered by a qualified health care provider. It is given as two (2) separate, consecutive intramuscular (IM) injections, 1 injection of tixagevimab 300mg and 1 injection of cilgavimab 300mg, preferably in the gluteus muscles. The patient is monitored for one hour in the facility after administration.

If a patient received tixagevimab 150mg and cilgavimab 150mg prior to the change in dosing in February 2022, the patient may receive an additional dose of tixagevimab 150 mg and cilgavimab 150 mg as soon as possible to complete a total dose of tixagevimab 300 mg and cilgavimab 300 mg.

What are potential side effects?

Adverse reactions reported in adults include dizziness (1%), fatigue (4%), headache (6%), insomnia (1%), among others. As with any other intramuscular injection, Evusheld should be given with caution to individuals with thrombocytopenia (low platelet) or any coagulation or bleeding disorder.

*****We offer Evusheld at our infusion facilities. Please, contact your provider to see if you may qualify for this treatment.**